Profile: Acura Pharmaceuticals Inc (ACUR.O)
28 Aug 2015
Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three proprietary platform technologies, which can be used to develop multiple products.
The Company's Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo Tablets (oxycodone HCl, CII), is an approved product utilizing Aversion in the United States and the Company has seven additional opioid products utilizing Aversion in various stages of development. The Company has also developed Impede Technology, which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. Its Impede Technology products include Nexafed and Nexafed Sinus Pressure + Pain product. The Company has multiple pseudoephedrine products in development utilizing its Impede Technology. The Company's third abuse deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.
The Company competes with Westport Pharmaceuticals and Egalet.
Acura Pharmaceuticals Inc
Suite 120, 616 N. North Court
PALATINE IL 60067